fbpx

Sanofi Abandons Deal For Rare Disease Drug Amid FTC’s Monopoly Concerns

Sanofi, which markets the two primary treatments for Pompe disease, was trying to add a third one by licensing rights to a Maze Therapeutics drug candidate with a different therapeutic approach. A Federal Trade Commission complaint alleges the deal amounts to a monopoly player taking out its competition.

The post Sanofi Abandons Deal For Rare Disease Drug Amid FTC’s Monopoly Concerns appeared first on Above the Law.

Related Articles

Responses

Your email address will not be published. Required fields are marked *